Furthermore, in the PAMELA Phase 2 trial, they concluded that HER2-E subtype is the predictor of pCR following trastuzumab and lapatinib without chemotherapy in early-stage HER2 + BC [63]. This evidence concerns the gene ERBB2 and breast cancer.